Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature.
Bevacizumab
Brain metastases
Gastro-intestinal tract metastases
Malignant meningioma
Systemic treatment
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
16 Apr 2019
16 Apr 2019
Historique:
received:
03
01
2019
accepted:
12
03
2019
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
6
8
2019
Statut:
epublish
Résumé
Meningioma is the most common adult primary intracranial tumor. Malignant meningioma is a rare variant of meningioma. The prognosis for the patients with these tumors is poor, due to the tumor's capacity for relapse and to develop distant metastases. These tumors can present the same evolutionary course as aggressive carcinoma. We report the case of distant brain and gastro-intestinal tract (GIT) metastases. A 78-year-old patient developed malignant meningioma with a Ki-67 proliferative index of 40%. According to guidelines, surgery followed by postoperative radiotherapy (RT) was performed. Three months after the end of RT, he presented histologically proven meningioma distant brain and GIT metastases. To our knowledge, this is the first case of meningioma GIT metastases. Also, we report the difficulty to confirm the diagnosis of meningioma metastases. Indeed, malignant meningioma has the same histopathological features as melanoma or carcinoma. The standard of care for the management of malignant meningioma is gross total surgery followed by postoperative radiotherapy. Metastatic meningioma is uncommon and no guidelines for the management of recurrent or metastatic meningioma have yet been published. However, several studies reported systemic therapeutic options such as antibody against VEGF, somatostatin analogs, PDGF-R, and VEGF-R tyrosine kinase inhibitors, in the case of recurrent or metastatic meningioma. We also made a review of the actual literature of systemic treatment options for metastatic meningioma.
Sections du résumé
BACKGROUND
BACKGROUND
Meningioma is the most common adult primary intracranial tumor. Malignant meningioma is a rare variant of meningioma. The prognosis for the patients with these tumors is poor, due to the tumor's capacity for relapse and to develop distant metastases. These tumors can present the same evolutionary course as aggressive carcinoma.
CASE DESCRIPTION
METHODS
We report the case of distant brain and gastro-intestinal tract (GIT) metastases. A 78-year-old patient developed malignant meningioma with a Ki-67 proliferative index of 40%. According to guidelines, surgery followed by postoperative radiotherapy (RT) was performed. Three months after the end of RT, he presented histologically proven meningioma distant brain and GIT metastases.
CONCLUSIONS
CONCLUSIONS
To our knowledge, this is the first case of meningioma GIT metastases. Also, we report the difficulty to confirm the diagnosis of meningioma metastases. Indeed, malignant meningioma has the same histopathological features as melanoma or carcinoma. The standard of care for the management of malignant meningioma is gross total surgery followed by postoperative radiotherapy. Metastatic meningioma is uncommon and no guidelines for the management of recurrent or metastatic meningioma have yet been published. However, several studies reported systemic therapeutic options such as antibody against VEGF, somatostatin analogs, PDGF-R, and VEGF-R tyrosine kinase inhibitors, in the case of recurrent or metastatic meningioma. We also made a review of the actual literature of systemic treatment options for metastatic meningioma.
Identifiants
pubmed: 30992070
doi: 10.1186/s12957-019-1596-6
pii: 10.1186/s12957-019-1596-6
pmc: PMC6469106
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Pagination
70Références
Clin Neurol Neurosurg. 2001 Apr;103(1):13-8
pubmed: 11311470
Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4
pubmed: 12633961
Cancer. 2004 Apr 1;100(7):1491-7
pubmed: 15042684
Hum Pathol. 2004 Nov;35(11):1413-8
pubmed: 15668900
Pathol Int. 2009 Feb;59(2):98-101
pubmed: 19154263
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406
pubmed: 19203844
J Neurooncol. 2010 Sep;99(3):379-91
pubmed: 20809251
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343
J Neurooncol. 2010 Sep;99(3):315-24
pubmed: 20838852
J Neurooncol. 2012 Aug;109(1):63-70
pubmed: 22535433
Int J Clin Exp Pathol. 2012;5(3):231-42
pubmed: 22558478
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
J Neurooncol. 2013 May;112(3):323-7
pubmed: 23404622
Neoplasma. 2013;60(5):480-5
pubmed: 23790165
J Neuropathol Exp Neurol. 1987 Jan;46(1):50-6
pubmed: 2432194
J Neurooncol. 2014 Mar;117(1):93-101
pubmed: 24449400
Cancer Chemother Pharmacol. 2014 May;73(5):919-23
pubmed: 24619496
Neuro Oncol. 2015 Jan;17(1):116-21
pubmed: 25100872
Neuro Oncol. 2015 Aug;17(8):1166-73
pubmed: 26008603
Neuro Oncol. 2016 Mar;18(3):401-7
pubmed: 26354929
Cancer Chemother Pharmacol. 2016 Jan;77(1):115-20
pubmed: 26659583
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Neurosurgery. 1989 Oct;25(4):514-22
pubmed: 2797389
J Neurosurg. 1993 Mar;78(3):456-62
pubmed: 8433149
Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8
pubmed: 8955436